---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-387310"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2026-09-10T12:16:11+00:00"
generated_at: "2026-09-10T12:20:09.498105+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics appoints Martine Zimmermann to board; BLA submission planned Q4 2026

## Summary
- Board expanded from 10 to 11 directors; Zimmermann appointed effective Sept 8, 2026, as Class III director with term to 2027 annual meeting.
- Compensation: option for 64,000 shares vesting monthly over 3 years; $40,000 annual retainer paid quarterly.
- Zimmermann brings 30+ years regulatory/quality experience; currently EVP at Inventiva, previously SVP at Ipsen and Alexion.
- Company reiterates planned BLA submission for aglatimagene besadenovec in Q4 2026; appointment supports commercial readiness.

## SEC filing metadata
- accession: 0001193125-26-387310
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2026-09-10T12:16:11+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/0001193125-26-387310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-20260906.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-387310
- JSON: https://secwatch.observer/filing/0001193125-26-387310.json
- Plain text: https://secwatch.observer/filing/0001193125-26-387310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.